Nucleix announces positive results in study detecting lung cancer

Israeli cancer detection company Nucleix has announced positive results from a clinical study evaluating its cutting-edge Lung EpiCheck blood test for early detection of lung cancer. The Lung EpiCheck blood test is based on a proprietary molecular biomarker technology, which combines new biochemical assays and sophisticated algorithms. The technology is based on identification and analysis of subtle changes in DNA methylation patterns, which is a powerful tool for distinguishing between cancer and healthy cells and thus for detection of tumors in the body.

SOCIAL MEDIA

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the
email and you’re good to go.

GOT IT !